Nat commun: scientists have found a new way to accelerate the development of cancer immunotherapy

February 11, 2020 news / BIOON / -- the ability of tumor mutation can make it avoid chemotherapy and other therapies and escape smoothly Therefore, in cancer treatment, promoting gene mutation of cancer cells may not be a reasonable way for researchers Recently, an international journal Nature communications was published In the previous study report, scientists from Mayo Clinic and other institutions analyzed mouse models and human cells and used a perverse method to study They found that when this method makes cancer cells resistant to chemotherapy, it also promotes tumor sensitivity to immunotherapy Therefore, this method may be able to successfully deal with multiple types of cancer Genome of tumor and individual patient Photo source: Dr Richard Ville, NIH researcher, said that after studying children's brain tumors and melanoma models, we found that high levels of apobec3b protein may drive higher tumors in mice At the same time, high level of apobec3b can also promote cancer cells to become sensitive to immunocheckpoint inhibitors, which is a major immunotherapy mechanism The researchers pointed out that when we put them into the environment of vaccine treatment, these mutations will produce new antibody binding sites, which are peptides that can be used as the main target of killing T cells When they are combined with checkpoint inhibitors, they may be able to be used as a means of cross tumor treatment The results of this study show that the cure rate of subcutaneous melanoma and brain tumor model is higher, and the therapeutic effect is better regardless of tumor type or site In addition, the researchers also found that not everyone needs a personalized treatment method Later researchers hope to be able to transfer the relevant research results to children's brain tumor through more in-depth research In clinical trials Original sources: Driscoll CB, schuelke Mr, kottke T, et al Apobec3b mediated corruption of the tumor cell immunity causes the regional neoepipes for cancer immunity NAT community 2020 Feb 7; 11 (1): 790 Doi: 10.1038 / s41467-020-14568-7